

Maria Teresa Pagliari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7553320/publications.pdf>

Version: 2024-02-01

18
papers

346
citations

1039880

9
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

660
citing authors

#	ARTICLE	IF	CITATIONS
1	The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients. <i>Haemophilia</i> , 2022, , .	1.0	1
2	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€PS study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1106-1114.	1.9	5
3	Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. <i>Blood Advances</i> , 2022, 6, 4031-4040.	2.5	5
4	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 513-521.	1.9	176
5	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. <i>Thrombosis Research</i> , 2021, 197, 132-137.	0.8	13
6	Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. <i>PLoS ONE</i> , 2021, 16, e0258675.	1.1	6
7	Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease. <i>Haemophilia</i> , 2020, 26, 298-305.	1.0	7
8	Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 666-669.	1.9	4
9	The ISTH Bleeding Assessment Tool and the risk of future bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 125-130.	1.9	32
10	Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed <i>de novo</i> mutation. <i>Haemophilia</i> , 2018, 24, e263-e266.	1.0	2
11	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2016, 115, 51-62.	1.8	14
12	von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients. <i>Haemophilia</i> , 2016, 22, e502-e511.	1.0	6
13	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0165665.	1.1	7
14	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1806-1814.	1.9	11
15	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 228-236.	1.9	18
16	The typeâ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1688-1698.	1.9	15
17	A synonymous (c.3390C>T) or a spliceâ€site (c.3380â€2A>C) mutation causes exonâ26 skipping in four patients with von Willebrand disease (2A/IIIE). <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1251-1259.	1.9	15
18	Interferon-Î2 but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. <i>Journal of Neuroimmunology</i> , 2011, 234, 161-164.	1.1	9